These preclinical findings greatly contributed to the approval of a phase 1 clinical trial entitled “A Phase I Study to Evaluate Safety and Preliminary Efficacy of Omacetaxine Mepesuccinate (Synribo) Combined with Venetoclax (Venclyxto) in Patients with Relapsed/Refractory Acute Myeloid Leukemia with Nucleophosmin (NPM1) Gene Mutation” (EudraCT n. The gene discussed is NPM1; the disease is acute myeloid leukemia.